Madrigal Pharmaceuticals, Inc. MDGL
Set alert
431.16 USD +0.79 +0.18%
At close · Nov 2
431.16 0.00 0.00%
After hours · Nov 2, 4:00 PM ET
425.33 Day range 436.74
412.35 52-week range 602.83
- YTD
- -25.96%
- 1 year
- +2.93%
- Open
- 430.04
- Prev close
- 430.36
- Mkt cap
- 9.96B
- Vol
- 495.09K
- Avg vol
- 270.00K
- EPS
- -12.87
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 425.33
- High
- 436.74
- Forward P/E
- 44.80
- Beta
- -1.00
- Short ratio
- 7.90
- Inst. own
- 104.52%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 498.66
- 200-d avg
- 499.95
- 1y target
- 685.22
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 685.22 +58.9% upside
Now 431.16
- Target (low)
- 533.00
- Target (mean)
- 685.22
- Target (high)
- 962.00
Ratings (0m) 19 18 buy · 1 hold · 0 sell
- Strong buy3
- Buy15
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 19
- 1 month ago 19
- 2 months ago 17
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -1.09 | -1.38 – -0.56 | -4.96 | +78.1% | 405.12M | +41.0% | 4 |
| Next quarter | -0.4225 | -0.77 – 0.11 | -2.57 | +83.6% | 446.28M | +39.0% | 4 |
| Current year | -6.49 | -7.38 – -4.91 | -12.73 | +49.0% | 1.53B | +59.4% | 4 |
| Next year | 9.63 | 7.01 – 12.84 | -6.49 | +248.3% | 2.12B | +38.8% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 23, 2026 | Citigroup | Initiated | — | Buy |
| Aug 4, 2026 | Wolfe Research | Upgrade | Peer Perform | Outperform |
| Aug 3, 2026 | Barclays | Maintained | Overweight | Overweight |
| Jul 29, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Jul 27, 2026 | Wells Fargo | Initiated | — | Overweight |
| Jun 11, 2026 | B of A Securities | Maintained | Neutral | Neutral |
| May 13, 2026 | Truist Securities | Maintained | Buy | Buy |
| May 7, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| May 7, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| May 6, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Feb 20, 2026 | B of A Securities | Maintained | Neutral | Neutral |
| Jan 28, 2026 | Barclays | Initiated | — | Overweight |
| Jan 20, 2026 | Citizens | Maintained | Market Outperform | Market Outperform |
| Dec 19, 2025 | Piper Sandler | Maintained | Overweight | Overweight |
| Dec 11, 2025 | B. Riley Securities | Maintained | Buy | Buy |
| Nov 21, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 20, 2025 | Oppenheimer | Maintained | Outperform | Outperform |
| Nov 19, 2025 | Truist Securities | Maintained | Buy | Buy |
| Nov 13, 2025 | Canaccord Genuity | Maintained | Buy | Buy |
| Nov 11, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 5, 2025 | Cantor Fitzgerald | Upgrade | Neutral | Overweight |
| Nov 5, 2025 | Citizens | Maintained | Market Outperform | Market Outperform |
| Nov 3, 2025 | B of A Securities | Upgrade | Underperform | Neutral |
| Oct 15, 2025 | Piper Sandler | Maintained | Overweight | Overweight |
| Oct 15, 2025 | Truist Securities | Initiated | — | Buy |
| Oct 10, 2025 | Oppenheimer | Maintained | Outperform | Outperform |
| Sep 29, 2025 | B. Riley Securities | Maintained | Buy | Buy |
| Sep 12, 2025 | Canaccord Genuity | Maintained | Buy | Buy |
| Aug 26, 2025 | TD Cowen | Maintained | Buy | Buy |
| Aug 20, 2025 | JMP Securities | Maintained | Market Outperform | Market Outperform |